Expanding precision oncology

With precision medicine, doctors tailor treatment to the molecular features of a person’s cancer. MSK scientists have identified hundreds of cancer-related mutations, proteins, and other traits, and pioneered new targeted therapies that take aim at them.

Scientists in lab coats, including MSK's Dr. David Solit, discuss research near a microscope.

Pinpointing molecular drivers of cancer today

For decades, MSK has led progress in precision medicine, turning discoveries about cancer biology into therapies tailored to the characteristics of an individual’s disease.

To develop targeted drugs that give patients more tomorrows

With donor support, MSK can continue to push the field of precision medicine forward and change outcomes for more people around the world.

  • Building on MSK-IMPACT, MSK is launching the Innovative Diagnostics Initiative, which brings MSK’s artificial intelligence and data science capabilities together with a new generation of clinical genomic tests.  
  • MSK-TARGET™, a part of this initiative, is an RNA sequencing test that offers even deeper insights into each person’s cancer. Recently approved by New York State for clinical validation, the test is being refined with data from thousands of patients — a step that could make it a future standard of care.
  • MSK’s Early Drug Development Service is exclusively focused on early-stage clinical trials and gives patients opportunities to access new precision treatments.

Progress made possible by the MSK Giving community

A milestone FDA approval
A milestone FDA approval

A clinical trial led by MSK resulted in the FDA approval for daraxonrasib (RasonqueTM) for pancreatic cancer. The drug that targets the KRAS mutation, which drives over 90% of pancreatic cancers.

Learn more
Translating research into cures
Translating research into cures

Through a transformative $100 million gift, longtime donors Fiona and Stanley Druckenmiller are supporting promising translational research at MSK through the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

Learn what donors can do
A triple threat
A triple threat

MSK helped lead a clinical trial that showed a new three drug combination — which includes two targeted treatments — improved survival rates for people with ER-positive, HER2-negative breast cancer.

Read more
Accelerating progress
Accelerating progress

Donor support, including from the Tow Foundation, has fueled advances in an emerging type of precision medicine called theranostics. An MSK clinical trial led to expanded FDA approval of a targeted treatment for prostate cancer.

Read more
Improving outcomes for everyone
Improving outcomes for everyone

MSK researchers discovered that some patients are more likely than others to be matched to precision treatments based on their genetic ancestry. They’re now seeking to better understand these disparities to improve care for all.

Read more
A milestone FDA approval
Translating research into cures
A triple threat
Accelerating progress
Improving outcomes for everyone

Help us make the next big leap in precision oncology

Make a gift
Donate to MSK to fund life-changing research and care.
Start a fundraiser
Invite your friends and family to join you in your mission.
Attend an event
Come to a fundraising event to show your support.
To discover more ways to partner in our work, email us.
Contact us
An MSK clinician smiles as she holds a stethoscope to a patient’s chest.

The MSK Campaign: Leading Science. Changing Lives.

The MSK community is raising $6 billion by 2030 to accelerate advances across six key strategic initiatives. Learn more and join us in our mission of ending cancer for life.

Learn more about The MSK Campaign